Samrat Pharmachem Ltd Intrinsic Value
SAMRATPH · Healthcare · Current price ₹233
Is Samrat Pharmachem Ltd undervalued?
DocStoX estimates the fair value of Samrat Pharmachem Ltd at ₹219 per share, versus the current market price of ₹233. That puts the stock about -6.0% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is high.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹216), Relative P/E (₹243), Graham floor (₹186). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹186 (bear) to ₹219 (base) to ₹252 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹233 versus an intrinsic value of ₹219, Samrat Pharmachem Ltd currently offers -6.0% of negative margin (i.e. a premium).
More on Samrat Pharmachem Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.